{"id":36172,"date":"2015-05-18T05:50:04","date_gmt":"2015-05-18T09:50:04","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=36172"},"modified":"2015-05-18T05:50:04","modified_gmt":"2015-05-18T09:50:04","slug":"celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials-36172","title":{"rendered":"Celladon Corp (NASDAQ:CLDN) Cutting Company Costs After Failure of Heart Treatment Drug Trials"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Celladon Corp (NASDAQ:CLDN)<\/strong> is going through a tough phase. The company is cutting out on its workforce to survive after the gene treatment drug for heart disease failed in its Phase 2B trial. The Mydicar drug for curing cardiac diseases failed to help increase survival rate or lower the rate of hospitalization in heart patients, and this has impacted the company&#8217;s market value. This therapy was the company&#8217;s hope of achieving a breakthrough in the heart failure treatment domain, and now all hopes have washed away.<\/p>\n<p style=\"text-align: justify;\">According to reports, the company is slashing its strength to almost half from the current staff of 34 biotechnologists in a bid to cut down on the company costs. Their development deals with Novasep and Lonza are also now not going to materialize as the collaboration with the two companies was for the development of the Mydicar drug, which is history now. The deals were going to provide a $15 million aid in manufacturing of the cardiac treatment.<\/p>\n<p style=\"text-align: justify;\"><strong>Company Struggling to Stay Afloat<\/strong><\/p>\n<p style=\"text-align: justify;\">A regulatory statement of the company affirmed that they had $70.6 million in cash and equivalents at the end of the March quarter. This was enough to help the company in working on other projects and new research that can help boost the confidence of its investors. The market sentiment has fallen past the failed attempts of the gene therapy, and the company is going to preserve the cash flows to understand the failure.<\/p>\n<p style=\"text-align: justify;\"><strong>Analyzing Possibilities on Future<\/strong><\/p>\n<p style=\"text-align: justify;\">Celladon&#8217;s Chief Executive Officer Krisztina Zsebo stated that the company was now mulling to carry out an extensive review of the study data on the Mydicar drug. This would help them in getting a better understanding of the negative results of the drug. Zsebo said that the company was also analyzing its cash resources and trying to figure out in the next clinical trials that they will be conducting for the treatment of other diseases.<\/p>\n<p style=\"text-align: justify;\">In a bid to boost the investor confidence and get a better market standing, the company is trying to take caution in choosing their next pathway. Meanwhile, analysts have been downgrading the share value after the company failed to meet the estimated growth in share rates in the last quarter.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Celladon Corp (NASDAQ:CLDN) is going through a tough phase. The company is cutting out on its workforce to survive after the gene treatment drug for [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":36173,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[11518,11520,11519],"stock_ticker":[],"class_list":["post-36172","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-celladon-corp-nasdaqcldn","tag-krisztina-zsebo","tag-nasdaqcldn","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Celladon Corp (NASDAQ:CLDN) Cutting Company Costs After Failure of Heart Treatment Drug Trials - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials-36172\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Celladon Corp (NASDAQ:CLDN) Cutting Company Costs After Failure of Heart Treatment Drug Trials - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Celladon Corp (NASDAQ:CLDN) is going through a tough phase. The company is cutting out on its workforce to survive after the gene treatment drug for [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials-36172\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-05-18T09:50:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2015\/05\/celladon-corp.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"530\" \/>\n\t<meta property=\"og:image:height\" content=\"298\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fiona Gibson\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fiona Gibson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials-36172#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials-36172\"},\"author\":{\"name\":\"Fiona Gibson\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e5ef7ff4b449e42e0b2e812283dba24e\"},\"headline\":\"Celladon Corp (NASDAQ:CLDN) Cutting Company Costs After Failure of Heart Treatment Drug Trials\",\"datePublished\":\"2015-05-18T09:50:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials-36172\"},\"wordCount\":384,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials-36172#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2015\/05\/celladon-corp.jpg\",\"keywords\":[\"Celladon Corp (NASDAQ:CLDN)\",\"Krisztina Zsebo\",\"NASDAQ:CLDN\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials-36172#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials-36172\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials-36172\",\"name\":\"Celladon Corp (NASDAQ:CLDN) Cutting Company Costs After Failure of Heart Treatment Drug Trials - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials-36172#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials-36172#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2015\/05\/celladon-corp.jpg\",\"datePublished\":\"2015-05-18T09:50:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials-36172#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials-36172\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials-36172#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2015\/05\/celladon-corp.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2015\/05\/celladon-corp.jpg\",\"width\":530,\"height\":298},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials-36172#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Celladon Corp (NASDAQ:CLDN) Cutting Company Costs After Failure of Heart Treatment Drug Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e5ef7ff4b449e42e0b2e812283dba24e\",\"name\":\"Fiona Gibson\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f92ca1ce6ecdb59f7bac42afaacd292b.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f92ca1ce6ecdb59f7bac42afaacd292b.jpeg\",\"caption\":\"Fiona Gibson\"},\"description\":\"Fiona is a finance graduate and an expert in analyzing market trends.\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\",\"https:\/\/x.com\/@fionahime\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/fiona-gibson\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Celladon Corp (NASDAQ:CLDN) Cutting Company Costs After Failure of Heart Treatment Drug Trials - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials-36172","og_locale":"en_US","og_type":"article","og_title":"Celladon Corp (NASDAQ:CLDN) Cutting Company Costs After Failure of Heart Treatment Drug Trials - Wall Street PR","og_description":"Celladon Corp (NASDAQ:CLDN) is going through a tough phase. The company is cutting out on its workforce to survive after the gene treatment drug for [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials-36172","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2015-05-18T09:50:04+00:00","og_image":[{"width":530,"height":298,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2015\/05\/celladon-corp.jpg","type":"image\/jpeg"}],"author":"Fiona Gibson","twitter_misc":{"Written by":"Fiona Gibson","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials-36172#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials-36172"},"author":{"name":"Fiona Gibson","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e5ef7ff4b449e42e0b2e812283dba24e"},"headline":"Celladon Corp (NASDAQ:CLDN) Cutting Company Costs After Failure of Heart Treatment Drug Trials","datePublished":"2015-05-18T09:50:04+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials-36172"},"wordCount":384,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials-36172#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2015\/05\/celladon-corp.jpg","keywords":["Celladon Corp (NASDAQ:CLDN)","Krisztina Zsebo","NASDAQ:CLDN"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials-36172#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials-36172","url":"https:\/\/cablemanpro.com\/wallstreetpr\/celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials-36172","name":"Celladon Corp (NASDAQ:CLDN) Cutting Company Costs After Failure of Heart Treatment Drug Trials - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials-36172#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials-36172#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2015\/05\/celladon-corp.jpg","datePublished":"2015-05-18T09:50:04+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials-36172#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials-36172"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials-36172#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2015\/05\/celladon-corp.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2015\/05\/celladon-corp.jpg","width":530,"height":298},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celladon-corp-nasdaqcldn-cutting-company-costs-after-failure-of-heart-treatment-drug-trials-36172#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Celladon Corp (NASDAQ:CLDN) Cutting Company Costs After Failure of Heart Treatment Drug Trials"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e5ef7ff4b449e42e0b2e812283dba24e","name":"Fiona Gibson","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f92ca1ce6ecdb59f7bac42afaacd292b.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f92ca1ce6ecdb59f7bac42afaacd292b.jpeg","caption":"Fiona Gibson"},"description":"Fiona is a finance graduate and an expert in analyzing market trends.","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr","https:\/\/x.com\/@fionahime"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/fiona-gibson"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/36172","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=36172"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/36172\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/36173"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=36172"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=36172"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=36172"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=36172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}